Chromatin regulation in schistosomes and histone modifying enzymes as drug targets
Mem. Inst. Oswaldo Cruz
; 106(7): 794-801, Nov. 2011. ilus
Artigo
em Inglês
| LILACS
| ID: lil-606641
Biblioteca responsável:
BR1.1
ABSTRACT
Only one drug is currently available for the treatment and control of schistosomiasis and the increasing risk of selecting strains of schistosome that are resistant to praziquantel means that the development of new drugs is urgent. With this objective we have chosen to target the enzymes modifying histones and in particular the histone acetyltransferases and histone deacetylases (HDAC). Inhibitors of HDACs (HDACi) are under intense study as potential anti-cancer drugs and act via the induction of cell cycle arrest and/or apoptosis. Schistosomes like other parasites can be considered as similar to tumours in that they maintain an intense metabolic activity and rate of cell division that is outside the control of the host. We have shown that HDACi can induce apoptosis and death of schistosomes maintained in culture and have set up a consortium (Schistosome Epigenetics Targets, Regulation, New Drugs) funded by the European Commission with the aim of developing inhibitors specific for schistosome histone modifying enzymes as novel lead compounds for drug development.
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Contexto em Saúde:
Doenças Negligenciadas
Problema de saúde:
Zoonoses
Base de dados:
LILACS
Assunto principal:
Schistosoma
/
Cromatina
/
Inibidores Enzimáticos
/
Histona Acetiltransferases
/
Histona Desacetilases
Limite:
Animais
Idioma:
Inglês
Revista:
Mem. Inst. Oswaldo Cruz
Assunto da revista:
Medicina Tropical
/
Parasitologia
Ano de publicação:
2011
Tipo de documento:
Artigo
País de afiliação:
França
Instituição/País de afiliação:
Institut Pasteur de Lille/FR